No Data
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfuncti
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Raises Target Price to $102
Wedbush analyst Andreas Argyrides maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and adjusts the target price from $86 to $102.According to TipRanks data, the analyst has a success rate of
Express News | Keros Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $102
Keros Therapeutics Initiated at Outperform by Oppenheimer
Keros Therapeutics Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Coverage On Keros Therapeutics With Outperform Rating, Announces Price Target of $102
Oppenheimer analyst Andreas Argyrides initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating and announces Price Target of $102.